Bafna Pharmaceuticals Limited has informed regarding Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 for Sale / Disposal of Manufacturing Unit of the Company
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bafna Pharmaceuticals has completed the sale of its manufacturing unit located at 13, S.V. Koil Street, Madhavaram, Chennai (Unit-I) to Navron Pharma Private Limited for a total consideration of Rs. 1.45 crore. The agreement was signed on June 23, 2025, and the transaction was completed on June 30, 2025. The disposed unit contributed only Rs. 11.53 lakh (0.08%) to the company's revenue and Rs. 89.88 lakh (1.55%) to its net worth as of March 31, 2025, making it a very small part of the business. The buyer is unrelated to the promoter group, and the deal is not a related party transaction. The company continues to operate its second manufacturing unit at Grantlyon Village, Chennai. Board and shareholder approvals for this sale were secured in August and September 2024.
Minimal impact on shareholders — the sold unit was immaterial to revenue (0.08%) and net worth (1.55%). The Rs. 1.45 crore inflow is small relative to the company's overall size, so this is largely a non-event for the stock. Investors should note that Bafna has consolidated its manufacturing to a single unit (Unit-II at Grantlyon), which could bring cost focus going forward.